M/S. Antraa Holding Ltd, a UAE-based investment company operating out of Jebel Ali Free Zone, came to NPCS with a clear mandate but no fixed project — they had capital ready and a healthcare sector focus, and needed credible, independent guidance on where to invest. After a structured opportunity screening process, our team identified IV fluid manufacturing for Southern and Eastern African markets as the strongest strategic fit for the client's objectives.

The case was compelling. IV fluids are WHO-classified essential medicines consumed daily across every tier of the healthcare system — hospitals, ICUs, surgical units, and clinics. Demand is stable, predictable, and driven by governments, public health agencies, and NGOs purchasing at volume on recurring contracts. Most of the region's supply is still imported, creating a genuine opening for a regionally based manufacturer. Antraa's location in Jebel Ali Free Zone strengthened the case further, offering direct logistics connectivity to East and Southern African ports.

We delivered a full feasibility study covering the sterile manufacturing process, GMP and regulatory requirements, raw material sourcing, and a detailed financial model with capital expenditure estimates, revenue projections, ROI, IRR, and payback period analysis. Everything was packaged into a bankable Detailed Project Report alongside a phase-wise implementation roadmap. The client left the engagement with a validated investment thesis and the confidence to formally commit to moving forward with project implementation.